| Amedisys Home Health | |
| 2900 North Hills Street, Meridian, Mississippi 39305 | |
| (601) 484-3293 | |
| Name | Amedisys Home Health |
|---|---|
| Location | 2900 North Hills Street, Meridian, Mississippi |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 257121 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 39057, 39301, 39303, 39304, 39305, 39307, 39320, 39323, 39325, 39326, 39327, 39328, 39330, 39332, 39335, 39336, 39337, 39338, 39342, 39345, 39347, 39350, 39352, 39354, 39355, 39356, 39358, 39360, 39363, 39364, 39365, 39366, 39367, 39439 |
| NPI Number | 1295779403 |
| Organization Name | MERIDIAN HMA INC |
| Doing Business As | RILEY HOME HEALTH |
| Address | 1504 20th Ave, Meridian, MS 39301 |
| Phone Number | 601-484-3293 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
| NPI Number | 1427220649 |
| Organization Name | AMEDISYS MISSISSIPPI, L.L.C. |
| Doing Business As | AMEDISYS HOME HEALTH |
| Address | 2900 N Hills St, Meridian, MS 39305 |
| Phone Number | 601-484-3293 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
| Quality Rating: |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 95.1 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 77.5 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 72.5 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.2 | 96.4 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 85.5 | 79.6 |
| How often patients got better at getting in and out of bed | 84.3 | 81.1 |
| How often patients got better at bathing | 89.3 | 82.3 |
| How often patients’ breathing improved | 89 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 96.1 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 80.7 | 75 |
| How often home health patients had to be admitted to the hospital | 19.9 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.7 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 99.6 | 94 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
The patient survey data of Amedisys Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 91 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 84 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 79 | 78 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective factor that works against this inflammation.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Health authorities in California have found a way a keeping awkward or embarrassing information on sexually transmitted disease (STD), right down to the minimum.
› Verified 8 days ago
Amedisys Home Health Location: 2900 North Hills Street, Meridian, Mississippi 39305 Ratings: Phone: (601) 484-3293 | |
Kindred At Home Location: 2600 Old North Hills Street, Meridian, Mississippi 39305 Ratings: Phone: (601) 482-5055 |